Overview

Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

Status:
Not yet recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to examine whether treatment with dapagliflozin plus insulin as compared with insulin alone (basal-bolus insulin) will result in similar blood glucose control and similar rate of complications in patients with diabetes, who are admitted to a hospital in a noncritical setting
Phase:
Phase 4
Details
Lead Sponsor:
Medanta, The Medicity, India
Treatments:
Dapagliflozin